Crossmark

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

Crossref DOI link: https://doi.org/10.1038/s41422-022-00612-2

Published Online: 2022-01-19

Published Print: 2022-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Zezhong

Zhou, Jie

Xu, Wei

Deng, Wei

Wang, Yanqun

Wang, Meiyu

Wang, Qian

Hsieh, Ming

Dong, Jingming

Wang, Xinling

Huang, Weijin https://orcid.org/0000-0002-4246-8889
Xing, Lixiao

He, Miaoling

Tao, Chunlin

Xie, Youhua https://orcid.org/0000-0002-2416-7708
Zhang, Yilong

Wang, Youchun https://orcid.org/0000-0001-9769-5141
Zhao, Jincun https://orcid.org/0000-0003-2515-5589
Yuan, Zhenghong https://orcid.org/0000-0003-0268-4891
Qin, Chuan https://orcid.org/0000-0002-6261-1232
Jiang, Shibo https://orcid.org/0000-0001-8283-7135
Lu, Lu https://orcid.org/0000-0002-2255-0391
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81822045)

National Natural Science Foundation of China (82041036)

National Natural Science Foundation of China (82041025)

National Natural Science Foundation of China (81630090)
License Information

Text and Data Mining valid from 2022-01-19

Version of Record valid from 2022-01-19
More Information

Article History

Received: 15 November 2021

Accepted: 3 January 2022

First Online: 19 January 2022

Competing interests

: L.L., S.J., Z.L., M.H., Y.Z., J.Z., Q.W., and W.X. filed a patent application for the STING agonist. The other authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below